Blood Samples From Patients on a Clinical Trial to CINV During HSCT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00900068|
Recruitment Status : Terminated
First Posted : May 12, 2009
Last Update Posted : May 9, 2017
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant.
|Condition or disease||Intervention/treatment|
|Breast Cancer Chronic Myeloproliferative Disorders Gestational Trophoblastic Tumor Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Nausea and Vomiting Neuroblastoma Ovarian Cancer Testicular Germ Cell Tumor||Other: immunoenzyme technique Other: laboratory biomarker analysis Other: medical chart review|
- To compare the amount of substance P in serum samples from patients with cancer treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation.
- To assess the changes in substance P over time to see if there is an optimal time shown by this physiologic correlate to discontinue substance P blockade after the chemotherapy regimen is completed in these patients.
OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes in substance P levels.
Patients' medical records are reviewed for demographic information, past history, and course of treatment.
|Study Type :||Observational|
|Actual Enrollment :||9 participants|
|Official Title:||Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation|
|Study Start Date :||August 2008|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||October 2009|
- Average, median, and mode for substance P levels at different times
- Correlation of substance P levels with patient response (emesis or not)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900068
|United States, Oregon|
|OHSU Knight Cancer Institute|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Joseph Bubalo, PharmD, BCPS, BCOP||OHSU Knight Cancer Institute|